KBC Group
NRIX icon

KBC Group’s Nurix Therapeutics NRIX Stock Holding History

KBC Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$52K Hold
2,192
– – ﹤0.01% 1714
2026
Q2 		$53K Hold
2,192
– – ﹤0.01% 1687
2026
Q1 		$34K Buy
+2,192
New +$36.3K ﹤0.01% 1768

Other funds holding NRIX

WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
RAM Investment Partners
RAM Investment Partners Bellevue, Washington $631M AUM 11.73% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

KBC Group's NRIX Position: Q3 2026 in Review

KBC Group held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 2,192 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

KBC Group first reported a position in NRIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $53K in Q2 2026. 20 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • KBC Group held 2,192 shares of Nurix Therapeutics worth $52K as of Q3 2026.
  • KBC Group left its Nurix Therapeutics share count unchanged in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1714 holding.
  • KBC Group first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Nurix Therapeutics position peaked at $53K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.